APUS
Apimeds Pharmaceuticals US, Inc.
Next earnings ≈ Aug 25, 2026 · est. from filing cadence
$0.90▼ -94.94%
over 1Y
L $0.86H $38.95
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W+4.9%
1M-31.8%
3M-52.1%
YTD-94.6%
1Y-94.9%
Hold
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity 0.07x).
Return on equity -3.9% · latest
Apimeds Pharmaceuticals US, Inc. shows limited reported revenue, and -3.9% ROE.
Supporting the case: conservative balance sheet (liabilities/equity 0.07x).
Is APUS a buy? The one-page verdict, explained →
The options angle
model · matches our verdictCovered call~60d expiry
- Long 100 shares @ ~0.90
- Short call 1 @ ~0.13 est
debit $77max +$23max −$76BE 0.77
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$747K | -$1.28M | -$11.9M |
| Net income | -$778K | -$1.39M | -$6.00M |
| Diluted EPS | -$0.17 | -$0.18 | -$0.55 |
| Net margin | — | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value—
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)-6.1%
Free cash flow-$8.98M
Total debt$20.0K
Net cash$1.62M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+53.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-05-15). Worth a closer look.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-26open ↗NT 10-QPeriod ending 2026-03-312026-05-15open ↗SCHEDULE 13D/AFiling2026-05-07open ↗8-KPeriod ending 2026-05-052026-05-05open ↗10-KPeriod ending 2025-12-312026-05-04open ↗8-KPeriod ending 2026-04-242026-05-04open ↗8-KPeriod ending 2026-04-172026-04-22open ↗8-KPeriod ending 2026-04-152026-04-16open ↗425Filing2026-04-09open ↗8-K/APeriod ending 2026-03-202026-04-09open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗SCHEDULE 13D/AFiling2026-03-30open ↗
Frequently asked
- Is Apimeds Pharmaceuticals US, Inc. (APUS) a buy?
- APUS currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.07x).
- What is Apimeds Pharmaceuticals US, Inc.'s quality score?
- APUS scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001894525, latest 10-Q filed 2026-05-26) · as of 6/22/2026, 11:30:10 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 22, 2026, 7:30 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.